Last edition
News about Market
Novo Nordisk India partners with Emcure Pharma to commercialise Poviztra in India
Under this agreement, Emcure becomes the first Indian company to hold exclusive rights for the distribution and commercialisation of the drug, expanding access to Novo Nordisk’s innovative semaglutide therapy for people living with overweight and obesity in the country.
Market | 10/11/2025 | By Dineshwori | 754
USFDA Approves Alembic Pharmaceuticals' Sumatriptan Single-Dose Autoinjector
Alembic Pharmaceuticals has received USFDA approval for its Abbreviated New Drug Application (ANDA) for Sumatriptan single-dose autoinjector, deemed therapeutically equivalent to GlaxoSmithKline’s Imitrex STATdose System in 4 mg/0.5 mL and 6 mg/0.5 mL strengths.
Market | 10/11/2025 | By Dineshwori | 211
Mankind Pharma Q2 Net Profit Falls 21 Percent to INR 520 Crore
Mankind Pharma reported a 21 percent year-on-year decline in consolidated net profit for the quarter ended September 30, 2025, with profit falling to approximately INR 520 crore from INR 661 crore in the same period last year.
Market | 07/11/2025 | By Darshana | 212
Zydus Lifesciences reported a robust performance for the second quarter ended September 30, 2025, with net profit rising over 38 percent to INR 1,258.6 crore, compared to INR 911.2 crore in the same quarter last year.
Market | 06/11/2025 | By Darshana | 242
USFDA Grants ODD to Zydus' Desidustat for Beta-Thalassemia Treatment
Desidustat, a Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor (HIF-PHI), has received Orphan Drug Designation (ODD) from the USFDA. The designation grants eligibility for up to seven years of marketing exclusivity upon approval and highlights Desidustat’s potential to boost haemoglobin and red blood cell production.
Market | 06/11/2025 | By Dineshwori | 190
Cipla to Acquire Inzpera Healthsciences for INR 110 Crore
Cipla Limited has announced that it will acquire a 100 percent stake in Inzpera Healthsciences Limited for a total consideration of approximately INR 110 crore.
Market | 05/11/2025 | By Darshana | 361
Kimberly-Clark to Acquire Tylenol Maker Kenvue in Over 40 Billion Dollar Deal
Kimberly-Clark has announced plans to acquire Kenvue, the company behind Tylenol and other well-known consumer health brands, in a cash-and-stock transaction valued at approximately 48.7 billion dollars.
Market | 04/11/2025 | By Darshana | 273
Merck Foundation Unveils USD 22 Million Programme to Enhance Cardiovascular Care across US
The Merck Foundation has launched a USD 22 million programme to strengthen cardiovascular care across the United States, awarding grants to 11 organisations to develop and implement evidence-based initiatives aimed at improving outcomes in underserved communities facing barriers to timely heart disease care.
Market | 04/11/2025 | By Dineshwori | 188
Glenmark to Launch 8.4% Sodium Bicarbonate Injection in the US Market
Glenmark Pharmaceuticals has announced its upcoming launch of 8.4% Sodium Bicarbonate Injection USP, 50 mEq/50 mL (1 mEq/mL) Single-Dose Vial in the US market.
Market | 04/11/2025 | By Dineshwori | 244
PharmaDrug Signs Definitive Agreement to Acquire Equity Interest in Canurta Inc
Under the Definitive Agreement, PharmaDrug will acquire up to a 40 percent equity interest in Canurta, to be completed in two tranches through the issuance of an aggregate of 83,645,316 common shares of PharmaDrug (PHRX Shares) at a deemed price equal to the 20-day volume-weighted average price immediately prior to each closing.
Market | 01/11/2025 | By Dineshwori | 241
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy